ArticleEClinicalMedicine2025

Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trial.

Jian-Xian Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.